Vasomotor symptoms (VMS) are among the most bothersome complaints of postmenopausal women. To date, the most widely studied and effective treatment for VMS is hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for treatment. However, over the years, additional estrogen formulations have been developed including transdermal patches; vaginal rings, creams, and tablets; and injectable preparations. Two newer formulations are transdermal estrogen spray and estradiol topical emulsion. This review evaluates the current literature assessing the use of these two newer formulations for the treatment of VMS associated with me...
Estrogen was approved as a hormone supplement in the 1940's to treat estrogen withdrawal symptoms in...
BACKGROUND: Vasomotor Symptoms are the most common and distressing menopausal complaint, for which w...
More than two-thirds of women experience hot flashes during menopause. Approximately 25% of women du...
Nathan W Kopper, Jennifer Gudeman, Daniel J ThompsonKV Pharmaceutical, St. Louis, MO, USAAbstract: V...
Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as many as 68.5% of women...
Elena M Umland, Laura FalconieriJefferson School of Pharmacy, Thomas Jefferson University, Philadelp...
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of a gel containing es...
Two-hundred and five (205) menopausal women with moderate to severe vasomotor symptoms, aged 39-64 y...
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of a gel containing es...
Objective: An overview of the current knowledge on the etiology and treatment of vasomotor symptoms ...
Vasomotor symptoms (VMS) experienced during menopause can negatively impact a woman’s quality of lif...
Background: Menopause is recognised to have occurred after 12 months of amenorrhoea for which there ...
© 2001 Informa plcObjective: To examine the effectiveness of oral hormone replacement therapy (HRT) ...
<p><b>Objectives:</b> Transdermal hormone replacement therapy is preferred for menopausal vasomotor ...
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to determine whet...
Estrogen was approved as a hormone supplement in the 1940's to treat estrogen withdrawal symptoms in...
BACKGROUND: Vasomotor Symptoms are the most common and distressing menopausal complaint, for which w...
More than two-thirds of women experience hot flashes during menopause. Approximately 25% of women du...
Nathan W Kopper, Jennifer Gudeman, Daniel J ThompsonKV Pharmaceutical, St. Louis, MO, USAAbstract: V...
Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as many as 68.5% of women...
Elena M Umland, Laura FalconieriJefferson School of Pharmacy, Thomas Jefferson University, Philadelp...
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of a gel containing es...
Two-hundred and five (205) menopausal women with moderate to severe vasomotor symptoms, aged 39-64 y...
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of a gel containing es...
Objective: An overview of the current knowledge on the etiology and treatment of vasomotor symptoms ...
Vasomotor symptoms (VMS) experienced during menopause can negatively impact a woman’s quality of lif...
Background: Menopause is recognised to have occurred after 12 months of amenorrhoea for which there ...
© 2001 Informa plcObjective: To examine the effectiveness of oral hormone replacement therapy (HRT) ...
<p><b>Objectives:</b> Transdermal hormone replacement therapy is preferred for menopausal vasomotor ...
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to determine whet...
Estrogen was approved as a hormone supplement in the 1940's to treat estrogen withdrawal symptoms in...
BACKGROUND: Vasomotor Symptoms are the most common and distressing menopausal complaint, for which w...
More than two-thirds of women experience hot flashes during menopause. Approximately 25% of women du...